Showing 701-710 of 7446 results for "".
DermWire TV: Merz Reorganizes; Amzeeq Approved; Restoration Merges with Venus Concept
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-merz-reorganizes-amzeeq-approved-restoration-merges-with-venus-concept/19694/Bob Rhatigan, newly appointed Global Chief Executive Officer of Merz Aesthetics, speaks about Merz reorganization. Amzeeq topical foam (Foamix Pharmaceuticals) approved for inflammatory, non-nodular, moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. FDA acUnderstanding a New Method of Assessing Psoriasis Severity
https://practicaldermatology.com/columns/clinical-focus-1/understanding-a-new-method-of-assessing-psoriasis-severity/23157/New method aims to improve access to systemic psoriasis therapy.New Effort Seeks to Address Antibiotic Resistance Via Legislation
https://practicaldermatology.com/topics/practice-management/new-effort-seeks-to-address-antibiotic-resistance-via-legislation/23125/Senators seek to support innovation and encourage responsible antibiotic prescribing.Atopic Dermatitis: Understanding the Impact
https://practicaldermatology.com/topics/atopic-dermatitis/atopic-dermatitis-understanding-the-impact/19667/For most AD patients, eczema is a bumpy ride. Even mild cases of atopic dermatitis can have a significant effect on people—and these effects range from quality of life impact to treatment costs. Peter Lio, MD describes his approach to a long-term eczema management plan.DermWire TV: Focus on Skin Cancer Awareness
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwire-tv-focus-on-skin-cancer-awareness/19613/For skin cancer awareness month, the AAD rolls out a new campaign, urging the public to “Practice Safe Sun.” The Skin Cancer Foundation is 40! Founded in 1979, the foundation made its mark in 1983 when it introduced its seal for sunscreens. SCF President, Deborah Sarnoff, MD discusses the foundationEczema Discovery; Ortho Dermatologics, Revision, Alastin Product Launches
https://practicaldermatology.com/topics/practice-management/dermwiretv-eczema-discovery-ortho-dermatologics-revision-alastin-product-launches/18353/Regeneron revealed that Dupixent generated sales of $120M within the first nine months of launch. Researchers have identified a possible treatment for moderate-to-severe atopic dermatitis: IL-22 blockade. Product launches or updates from Revision Skincare, Alastin Skincare, Ortho Dermatologics, andGalderma's Differin Goes OTC, CoolSculpting Approved for Upper Arms, ZO Skin Acquires ReFissa
https://practicaldermatology.com/series/dermwire-tv/galderma-s-differin-goes-otc-coolsculpting-approved-for-upper-arms-zo-skin-acquires-refissa/18549/Galderma's Differin Gel formulation of adapalene 0.1% is now available over the counter at major retail and drug stores in the US. ZELTIQ® Aesthetics' CoolSculpting is now FDA-cleared for fat reduction in the upper arms. ZO Skin Health has acquired the worldwide rights to ReFissa from Suneva MedicalHow Do Dermatologists Handle “No-Show Appointments”?
https://practicaldermatology.com/youngmd-connect/resident-resource-center/how-do-dermatologists-handle-no-show-appointments/20892/An online survey of dermatologists across the US is enlightening.Aubio Launches, Updates from Prescriber's Choice, BioPharmX
https://practicaldermatology.com/topics/practice-management/dermwiretv-aubio-launches-updates-from-prescriber-s-choice-biopharmx/18584/In this edition of DermWireTV, Aubio launches OTC treatment for cold sores with backing from Paul Mitchell partner. Prescriber's Choice facilitates in-office prescription dispensing. BioPharmX enrolls phase 2b trial for topical minocycline and Merz acquires ONLight Sciences, maker of PFD patch for tLaser hair removal in darker skin types, challenges and technological advances for treatment
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/laser-hair-removal-in-darker-skin-types-challenges-and-technological-advances-for-treatment/18800/Andrew Alexis, MD discusses laser hair removal treatment challenges in patients with higher Fitzpatrick skin types, and how recent advances in technology have been able to address these to deliver effective treatment with minimal pain.